Rubitab 50

Clomiphene citrate is a triarylethylene compound. It is a non-steroidal agent, which stimulates ovulation in a high percentage of appropriately selected anovulatory women.

Benefits

Clomiphene citrate is a triarylethylene compound. It is a non-steroidal agent, which stimulates ovulation in a high percentage of appropriately selected anovulatory women.

Dosage

The recommended dose for the first course of RUBITAB 50 is 50 mg (1 tablet) daily for 5 days. Therapy may be started at any time in the patient who has had no recent uterine bleeding. If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs before therapy, the regimen of 50 mg daily for 5 days should be started on or about the fifth day of the cycle. When ovulation occurs at this dosage, there is no advantage to increasing the dose in subsequent cycles of treatment.

If ovulation appears not to have occurred after the first course of therapy, a second course of 100 mg daily (two 50 mg tablets given as a single dose) for 5 days should be given. This course may be started as early as 30 days after the previous one. Increase of the dosage or duration of therapy beyond 100 mg per day for 5 days should not be undertaken.

The majority of patients who are going to respond will respond to the first course of therapy, and three courses should constitute an adequate therapeutic trial. If ovulatory menses did not yet occur, the diagnosis should be re-evaluated. Treatment beyond this is not recommended in the patient who does not exhibit evidence of ovulation. Ovulation most often occurs from 6-12 days after a course of RUBITAB 50 thus the importance of properly timed coitus cannot be over-emphasised. For regularity of cyclic ovulatory response, it is also important that each course of RUBITAB 50 be started on or about the fifth cycle day, once ovulation has been established.

RUBITAB 50 therapy is not effective in patients in whom primary pituitary or normal ovarian failure precludes the possibility of stimulating normal function. Some anovulatory patients who appear to respond to RUBITAB 50, but either do not ovulate or whose luteal phases are so short that the opportunity to conceive is limited may benefit by having the course of RUBITAB 50 followed by injections of human chorionic gonadotrophin (HCG) at about the expected time of ovulation. Infertile patients with polycystic ovary syndrome who have not responded to wedge resection of the ovary may respond to RUBITAB 50.

More about the product

Each tablet contains:
50 mg clomiphene citrate
Contains sugar (sucrose: 45 mg/tablet and lactose: 119,138 mg/tablet)
Excipients: starch, iron oxide, talc, colloidal anhydrous silica, hydroxypropyl methylcellulose, magnesium stearate